Sangeetha Venugopal, MD, MS

Sangeetha Venugopal, MD, MS, discusses other notable myelofibrosis data from the 2024 ASH Annual Meeting.

Sangeetha Venugopal, MD, MS, discusses data from the BOREAS trial for navtemadlin in relapsed/refractory myelofibrosis.

Sangeetha Venugopal, MD, MS, discusses post hoc overall survival data for pacritinib in myelofibrosis.

Sangeetha Venugopal, MD, MS, discusses the relationship between thrombocytopenia and anemia on disease progression in myelofibrosis

Sangeetha Venugopal, MD, MS, discusses challenges with low-dose ruxolitinib in myelofibrosis.

Sangeetha Venugopal, MD, MS, discusses factors that inform JAK inhibitor selection in myelofibrosis.

Sangeetha Venugopal, MD, MS, discusses pivekimab sunirine (PVEK), a novel CD123-targeting antibody-drug conjugate for blastic plasmacytoid dendritic cell neoplasm (BPDCN). PVEK showed promising response rates in treatment-naïve BPDCN patients in an early trial and was reasonably well-tolerated without concerning safety signals. Its FDA breakthrough therapy designation in relapsed/refractory BPDCN was based on phase 1 data suggesting good efficacy even after tagraxofusp (TAG). Early trials also support PVEK's potential in CD123+ acute myeloid leukemia, both as monotherapy and when combined with other agents like azacitidine and venetoclax.

Sangeetha Venugopal, MD, MS, provides an overview of how patients with blastic plasmacytoid dendritic cell neoplasms (BPDCN) are diagnosed.

Sangeetha Venugopal, MD, MS, discusses the importance of increasing awareness of blastic plasmacytoid dendritic cell neoplasm to improve early diagnosis and treatment for patients with BPDCN at academic centers.